

Office of Directorate General of Foreign Trade
New Delhi -0

Para 4.7 Decision

MEETING NUMBER : 5/82-ALC4/2009 MEETING DATE : 05.05.2009

The Meeting No5/82 in the year 2009-10 to consider the cases under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2004-09 pertaining to products falling in Chapter 29 and 30 scheduled to be held on 05.05.2009 was actually held on **26.05.2009** under the Chairmanship of Jt. DGFT, Shri Anil Aggarwal in his chamber.

Following members were present:-

1. Shri Jasbir Singh, IA, Department of C&PC
2. Shri D.N. Mathur, Dy. IA, Department of Pharmaceuticals
3. Shri Rajinder Pal Singh, Dy. DGFT
4. Shri Shyam Lal, FTDO

At the outset, minutes of Norms Committee Meeting No.1/82 dated 12.05.2009 and 2/82 dated 12.05.2009 were ratified by the Committee.

Case No.B-35	M/S Suven Life Sciences Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00627/AM09
Meeting Date: 05.05.2009	RA F.No.09/24/040/00044/AM09
Adv.Lic.No.0910034059 dated 26.05.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-36	M/S Suven Life Sciences Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/01662/AM09
Meeting Date: 05.05.2009	RA F.No.09/24/040/00393/AM09
Adv.Lic.No.0910037114 dated 18.02.2009	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to amend the description of export product to read as "Tetrazole Aldehyde". As regards enhancement in the quantity of inputs, it was decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-37	M/S Suven Life Sciences Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00873/AM09
Meeting Date: 05.05.2009	RA F.No.09/24/040/00189/AM09
Adv.Lic.No.0910035022 dated 12.08.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting	

decided to amend the description of export product to read as “Tetrazole Aldehyde”. As regards enhancement in the quantity of inputs, it was decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.

Case No.B-38	M/S Suven Life Sciences Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00683/AM09
Meeting Date: 05.05.2009	RA F.No.09/24/040/00080/AM09
Adv.Lic.No.0910034199 dated 06.06.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to amend the description of export product to read as “Tetrazole Aldehyde”. As regards enhancement in the quantity of inputs, it was decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-39	M/S Suven Life Sciences Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00543/AM08
Meeting Date: 05.05.2009	RA F.No.09/24/040/00450/AM08
Adv.Lic.No.0910032659 dated 15.01.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-40	M/S S.K. Age Exports
Norms Committee Meeting No.5/10	F.No.01/94/180/00998/AM09
Meeting Date: 05.05.2009	Adv.Lic.No.0310324570 dated 04.04.2005 Adv.Lic.No.0310324569 dated 04.04.2005 Adv.Lic.No.0310335401 dated 22.06.2005 Adv.Lic.No.0310335402 dated 22.06.2005
Committee considered case as per agenda and decided to seek comments of DCGI. Accordingly, case was deferred for 23.06.2009.	

Case No.B-41	M/S Grand Organics Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/01568/AM07
Meeting Date: 05.05.2009	RA F.No.17/24/040/00068/AM07
Adv.Lic.No.1710001513 dated 12.01.2007	
Committee considered case as per agenda and decided to forward a copy of decision taken in 3/83 meeting held on 18.04.2007 to RA.	

--	--

Case No.B-42	M/S Concord Biotech Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/01035/AM09
Meeting Date: 05.05.2009	RA F.No.08/24/040/00138/AM09
Adv.Lic.No.0810074890 dated 22.09.2008	
Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.	

Case No.B-43	M/S Fine Organics Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00392/AM09
Meeting Date: 05.05.2009	RA F.No.03/94/040/00136/AM09
Adv.Lic.No.0310471547 dated 16.05.2008	
Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.	

Case No.B-44	M/S Fine Organics Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00587/AM09
Meeting Date: 05.05.2009	RA F.No.03/94/040/00278/AM09
Adv.Lic.No.0310474948 dated 16.06.2008	
Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.	

Case No.B-45	M/S Fine Organics Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00737/AM09
Meeting Date: 05.05.2009	RA F.No.03/94/040/00375/AM09
Adv.Lic.No.0310478323 dated 11.07.2008	
Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.	

Case No.B-46	M/S Cipla Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/162/00901/AM09
Meeting Date: 05.05.2009	RA F.No.03/94/040/00797/AM09
Adv.Lic.No.0310494625 dated 18.11.2008	

Committee considered case as per agenda and in light of written comments forwarded by Department of Pharmaceuticals vide their U.O. No.35011/241/2008-PI-III dated 17.03.2009 and in consultation with technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export product	Export Qty.	Sl.No.	Import items	Qty. allowed
Nevirapine 200mg tablet [Nevirapine 204 mg/tablet]	1 No.	1.	3-(2-Chloro-3-pyridine-carbonyl)-amino-2-chloro-4-methyl pyridine/(NVP(II) compound)	1.428 kg/kg of Nevirapine

Nevirapine Oral solution 50 mg/5ml, 100ml bottle [Nevirapine 1020 mg/100 ml bottle]	1 No.	2.	Cyclopropylamine	0.57 kg/kg of Nevirapine
		3.	Diglyme	2.76 kg/kg of Nevirapine
		4.	Calcium Oxide	0.55 kg/kg of Nevirapine
		5.	Sodium Hydride	0.44 kg/kg of Nevirapine
		6.	Ethyl Acetate	1.70 kg/kg of Nevirapine

RA concerned may take further necessary action as per above decision of NC.

Case No.B-47	M/S Torrent Pharmaceuticals Ltd
Norms Committee Meeting No.5/10	F.No.01/82/050/01503/AM09
Meeting Date: 05.05.2009	RA F.No.08/24/040/00188/AM09
Adv.Lic.No.0810076697 dated 15.12.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-48	M/S Mohini Organics Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/01075/AM09
Meeting Date: 05.05.2009	RA F.No.03/95/040/00235/AM09
Adv.Lic.No.0310487970 dated 26.09.2008	
Committee decided to defer case for 09.06.2009 for comments of Department of C&PC.	

Case No.B-49	M/S Siddi Vinataka Spechem Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/87/050/01441/AM06
Meeting Date: 05.05.2009	RA F.No.07/24/040/00915/AM06
Adv.Lic.No.0710043512 dated 06.03.2006	
Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.	

Case No.B-50	M/S Morepen Laboratories Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00530/AM09
Meeting Date: 05.05.2009	RA F.No.05/24/040/00956/AM08
Adv.Lic.No.0510218438 dated 25.03.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting	

decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.

Case No.B-51	M/S Morepen Laboratories Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00798/AM09
Meeting Date: 05.05.2009	RA F.No.05/24/040/00270/AM09
Adv.Lic.No.0510224498 dated 28.07.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-52	M/S Morepen Laboratories Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00797/AM09
Meeting Date: 05.05.2009	RA F.No.05/24/040/00269/AM09
Adv.Lic.No.0510224493 dated 28.07.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-53	M/S Alchymars ICM Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/83/050/00016/AM08
Meeting Date: 05.05.2009	RA F.No.05/24/040/00501/AM07
Adv.Lic.No.0410088727 dated 02.04.2007	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-54	M/S Srini Pharmaceuticals Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00623/AM09
Meeting Date: 05.05.2009	RA F.No.09/24/40/00069/AM09
Adv.Lic.No.0910034081 dated 27.05.2008	
Committee considered case as per agenda and in consultation with technical authority present in meeting decided to maintain status quo as there is no justification for enhancement in the quantity of inputs.	

Case No.B-55	M/S Mahavir Dyechem
Norms Committee Meeting No.5/10	F.No.01/82/050/01813/AM07
Meeting Date: 05.05.2009	RA F.No.52/24/040/00006/AM07
Adv.Lic.No.5210021288 dated 15.03.2007	
Committee considered case as per agenda and in light of written comments forwarded by Chemical Division of C&PC vide their O.M. No.14010/118/2004/Ch.III, signed copy handed over in the meeting and in consultation with	

technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
2-(3-Amino Phenyl Sulfonamide) Naphthalene 6,8 Disulfonic Acid	1 MT.	1.	Beta Naphthol	0.875 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.B-56	M/S Resonance Laboratories Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00987/AM09
Meeting Date: 05.05.2009	RA F.No.07/24/040/00316/AM09
Adv.Lic.No.0710059630 dated 08.09.2008	

Committee considered case as per agenda and in light of written comments forwarded by Chemical Division of C&PC vide their U.O. No.14010/110/2008/Ch.II dated 04.05.2009 and in consultation with technical authority present in meeting, decided to revise norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
2,4-Bis-{{4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl)-6-(4-methoxyphenyl)-1,3,5-triazine	1 Kg.	1.	2,4-Bis-(resorcin-4-yl)-6-)4-methoxyphenyl) 1,3,5-triazine 80%	1.067 kg
		2.	2-Ethyl hexyl chloride (Iso-Ortho Chloride	1.003 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.B-57	M/S Resonance Laboratories Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00525/AM09
Meeting Date: 05.05.2009	RA F.No.07/24/040/00081/AM09
Adv.Lic.No.0710057574 dated 26.05.2008	

Committee considered case as per agenda and in light of written comments forwarded by Chemical Division of C&PC vide their U.O. No.14010/110/2008/Ch.II dated 04.05.2009 and in consultation with technical authority present in meeting, decided to revise norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-

Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
2,4-Bis-{{4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl)-6-(4-methoxyphenyl)-1,3,5-triazine	1 Kg.	1.	2,4-Bis-(resorcin-4-yl)-6-)4-methoxyphenyl) 1,3,5-triazine	1.067 kg
		2.	2-Ethyl hexyl chloride (Iso-Ortho Chloride	1.003 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.B-58	M/S Resonance Laboratories Pvt. Ltd.			
Norms Committee Meeting No.5/10	F.No.01/82/050/01578/AM09			
Meeting Date: 05.05.2009	RA F.No.07/24/040/00588/AM09			
Adv.Lic.No.0710062565 dated 27.01.2009				
Committee considered case as per agenda and in light of written comments forwarded by Chemical Division of C&PC vide their U.O. No.14010/110/2008/Ch.II dated 04.05.2009 and in consultation with technical authority present in meeting, decided to revise norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-				
Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
2,4-Bis-[[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl]-6-(4-methoxyphenyl)-1,3,5-triazine	1 Kg.	1.	2,4-Bis-(resorcin-4-yl)-6-(4-methoxyphenyl) 1,3,5-triazine	1.067 kg
		2.	2-Ethyl hexyl chloride (Iso-Ortho Chloride	1.003 kg
RA concerned may take further necessary action as per above decision of NC.				

Case No.B-59	M/S Redox Pharmachem Pvt. Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/050/00440/AM08
Meeting Date: 05.05.2009	RA F.No.05/24/040/00500/AM08
Adv.Lic.No.0510210770 dated 18.10.2007	
Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.	

Case No.C-3	M/S Aurobindo Pharma Ltd.
Norms Committee Meeting No.5/10	F.No.01/82/162/00881/AM08
Meeting Date: 05.05.2009	
Committee considered case as per agenda for fixation of SION and decided to examine the case on file.	

1	Case No.:2/27/82-ALC4/2008	Party Name:AUCTUS PHARMA LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved
	HQ File :01/82/050/01019/AM09/	RLA File :09/24/040/00216/AM09/	Lic.No/Date:0910035277 16.09.2008	
	Decision :Withdrawn as the case has already been approved by NC in its 2/82 meeting held on 12.05.2009.			

2	Case No.:6/46/82-ALC4/2008	Party Name:PIONEER LABORATORIES PVT. LTD.,	Meet No/Date:5/82-ALC4/2009	Status:Case
---	----------------------------	--	-----------------------------	-------------

			05.05.2009	Deferred
	HQ File :01/82/050/01588/AM09/	RLA File :11/24/040/00069/AM09/	Lic.No/Date:1110019460 23.01.2009	Defer Date:23.06..2009
	Decision :Committee considered case as per agenda and observed that the firm has been requested to furnish complete description of export product and import item No.1 and technical details as per Appendix 33 vide letter dated 02.04.2009, but no reply has been received. It was, therefore, decided to await reply of firm and defer case for 23.06.2009.			

3	Case No.:22/46/82-ALC4/2008	Party Name:SARNA CHEMICALS PVT.LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/01604/AM09/	RLA File :03/95/040/00854/AM09/	Lic.No/Date:0310504692 30.01.2009	Defer Date:23.06.2009
	Decision :Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

4	Case No.:1/5/82-ALC4/2009	Party Name:VIVIMED LABS LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00034/AM10/	RLA File :09/24/040/00005/AM10/	Lic.No/Date:0910037716 22.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

5	Case No.:2/5/82-ALC4/2009	Party Name:S.R.S.PHARMACEUTICALS PVT. LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved										
	HQ File :01/82/050/00035/AM10/	RLA File :03/95/040/00236/AM09/	Lic.No/Date:0310516665 22.04.2009											
	Decision : Committee considered case as per agenda and in light of earlier decision taken in 10/08 meeting held on 10.07.2007 vide case No.A-300 and in consultation with technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-													
	<table border="1"> <thead> <tr> <th>Export product</th><th>Exp. Qty.</th><th>Sl.No.</th><th>Import items</th><th>Qty. allowed</th></tr> </thead> <tbody> <tr> <td>Cefuroxime 750 mg Injection USP Each vial containing Cefuroxime Sodium USP equivalent to Cefuraxime 750 mg 10 ml vial</td><td>1 No.</td><td>1.</td><td>Cefuroxime Sodium Sterile</td><td>817.50 mg/vial</td></tr> </tbody> </table>				Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed	Cefuroxime 750 mg Injection USP Each vial containing Cefuroxime Sodium USP equivalent to Cefuraxime 750 mg 10 ml vial	1 No.	1.	Cefuroxime Sodium Sterile	817.50 mg/vial
Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed										
Cefuroxime 750 mg Injection USP Each vial containing Cefuroxime Sodium USP equivalent to Cefuraxime 750 mg 10 ml vial	1 No.	1.	Cefuroxime Sodium Sterile	817.50 mg/vial										
	RA concerned may take further necessary action as per above decision of NC.													

6	Case No.:3/5/82-ALC4/2009	Party Name:LUPIN LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved
---	---------------------------	--------------------------	---	-------------------------

	HQ File :01/82/050/00036/AM10/	RLA File :03/95/040/01017/AM09/	Lic.No/Date:0310516807 22.04.2009	
	Decision :Committee decided to close the case as Advance Authorisation has been issued under para 4.7.1 of HBP.			

7	Case No.:4/5/82-ALC4/2009	Party Name:ALEMBIC LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00037/AM10/	RLA File :34/24/040/00242/AM09/	Lic.No/Date:3410024018 22.04.2009	Defer Date:23.06.2009
	Decision :Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

8	Case No.:5/5/82-ALC4/2009	Party Name:ONEIRO CHEMICALS LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00038/AM10/	RLA File :34/24/040/00009/AM10/	Lic.No/Date:3410024019 22.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

9	Case No.:6/5/82-ALC4/2009	Party Name:GULBRANDSEN CHEMICALS PVT LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00039/AM10/	RLA File :34/24/040/00007/AM10/	Lic.No/Date:3410024025 22.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

10	Case No.:21/32/82-ALC4/2008	Party Name:VARUN MEDIMPEX INC.	Meet No/Date:53/82-ALC4/2008 24.03.2009	Status:Case Deferred
	HQ File :01/82/050/01196/AM09/	RLA File :05/24/040/00347/AM09/	Lic.No/Date:0510229889 23.10.2008	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of DIPP.			

11	Case No.:8/5/82-ALC4/2009	Party Name:HALDIA PETROCHEMICALS LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00041/AM10/	RLA File :02/24/040/00013/AM10/	Lic.No/Date:0210125805 23.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of PC Division of Department of C&PC.			

12	Case No.:9/5/82-ALC4/2009	Party Name:GURUDEV DYESTUFF INDIA PVT.LTD.	Meet No/Date:5/82-ALC4/2009	Status:Case
----	---------------------------	--	-----------------------------	-------------

			05.05.2009	Deferred
	HQ File :01/82/050/00042/AM10/	RLA File :08/24/040/00247/AM09/	Lic.No/Date:0810079511 23.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

13	Case No.:10/5/82-ALC4/2009	Party Name:HIKAL LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00043/AM10/	RLA File :03/94/040/01024/AM09/	Lic.No/Date:0310517064 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

14	Case No.:11/5/82-ALC4/2009	Party Name:HEMA DYE CHEM PVT. LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved										
	HQ File :01/82/050/00044/AM10/	RLA File :03/94/040/00022/AM10/	Lic.No/Date:0310517069 24.04.2009											
	Decision : Committee considered case as per agenda and in light of written comments forwarded by Chemical Division of C&PC vide their U.O. No.14010/50/2007-Ch.II, signed copy handed over in the meeting and in consultation with technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-													
	<table border="1"> <thead> <tr> <th>Export product</th><th>Exp. Qty.</th><th>Sl.No.</th><th>Import items</th><th>Qty. allowed</th></tr> </thead> <tbody> <tr> <td>2-Chloro-1 4-Dimethoxy Benzene (CLHQDME)</td><td>1 MT.</td><td>1.</td><td>1,4-Dihydroxy Benzene</td><td>0.692 kg</td></tr> </tbody> </table>				Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed	2-Chloro-1 4-Dimethoxy Benzene (CLHQDME)	1 MT.	1.	1,4-Dihydroxy Benzene	0.692 kg
Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed										
2-Chloro-1 4-Dimethoxy Benzene (CLHQDME)	1 MT.	1.	1,4-Dihydroxy Benzene	0.692 kg										
	RA concerned may take further necessary action as per above decision of NC.													

15	Case No.:12/5/82-ALC4/2009	Party Name:DORF-KETAL CHEMICALS INDIA PVT.LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved
	HQ File :01/82/050/00045/AM10/	RLA File :03/94/040/01114/AM09/	Lic.No/Date:0310517072 24.04.2009	
	Decision : Committee decided to close the case as Advance Authorisation has been issued under para 4.7.1 of HBP.			

16	Case No.:13/5/82-ALC4/2009	Party Name:CIPLA LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00046/AM10/	RLA File :03/94/040/00024/AM10/	Lic.No/Date:0310517091 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

17	Case No.:14/5/82-ALC4/2009	Party Name:MALLADI DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00047/AM10/	RLA File :04/24/040/00002/AM10/	Lic.No/Date:0410104217 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

18	Case No.:15/5/82-ALC4/2009	Party Name:ALKYL AMINES CHEMICALS LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00048/AM10/	RLA File :03/94/040/00401/AM09/	Lic.No/Date:0310517118 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of C&PC.			

19

Case No.:16/5/82-ALC4/2009	Party Name:MERCK LIMITED	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved	
HQ File :01/82/050/00049/AM10/	RLA File :03/95/040/00034/AM10/	Lic.No/Date:0310517138 24.04.2009		
Decision : Committee considered case as per agenda and in light of earlier decision taken in 31/82 meeting held on 04.12.2007 vide case No.954/21/82-ALC4/2007 and in consultation with technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-				
Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
DL-Alpha Tocopherol Acetate USP (Vitamin E Acetate USP)	1 Kg.	1.	Isophytol	0.738 kg
		2.	2,3,5-Trimethyl Hydroquinone	0.385 kg
RA concerned may take further necessary action as per above decision of NC.				

20	Case No.:17/5/82-ALC4/2009	Party Name:METROPOLITAN OVERSEAS LIMITED,	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved
	HQ File :01/82/050/00050/AM10/	RLA File :03/95/040/00046/AM10/	Lic.No/Date:0310517197 24.04.2009	
	Decision : Committee decided to close the case as Advance Authorisation has been issued under para 4.7.1 of HBP.			

21	Case No.:18/5/82-ALC4/2009	Party Name:RANBAXY LABORATORIES LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00051/AM10/	RLA File :05/24/040/00019/AM10/	Lic.No/Date:0510240287 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

22	Case No.:19/5/82-ALC4/2009	Party Name:RANBAXY LABORATORIES LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00052/AM10/	RLA File :05/24/040/00015/AM10/	Lic.No/Date:0510240292 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

23	Case No.:20/5/82-ALC4/2009	Party Name:RANBAXY LABORATORIES LTD	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Deferred
	HQ File :01/82/050/00053/AM10/	RLA File :05/24/040/00014/AM10/	Lic.No/Date:0510240296 24.04.2009	Defer Date:23.06.2009
	Decision : Committee decided to defer case for 23.06.2009 for comments of Department of Pharmaceuticals.			

24	Case No.:21/5/82-ALC4/2009	Party Name:RATNAGIRI CHEMICALS PVT. LTD.	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved
	HQ File :01/82/050/00054/AM10/	RLA File :03/95/040/00039/AM10/	Lic.No/Date:0310517260 24.04.2009	
	Decision : Committee decided to close the case as Advance Authorisation has been issued under para 4.7.1 of HBP.			

25

Case No.:22/5/82-ALC4/2009	Party Name:KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.,	Meet No/Date:5/82-ALC4/2009 05.05.2009	Status:Case Approved	
HQ File :01/82/050/00055/AM10/	RLA File :07/24/040/00026/AM10/	Lic.No/Date:0710064352 27.04.2009		
Decision : Committee considered case as per agenda and in light of earlier decision taken in 10/08 meeting held on 10.07.2007 vide case No.A-300 and in consultation with technical authority present in meeting, decided to ratify norms under para 4.7 of HBP as per details below or as applied by firm whichever is lower:-				
Export product	Exp. Qty.	Sl.No.	Import items	Qty. allowed
Cefuroxime 750 mg Injection USP Each vial containing Cefuroxime Sodium USP equivalent to Cefuraxime 750 mg 10 ml vial	1 No.	1.	Cefuroxime Sodium Sterile	817.50 mg/vial
RA concerned may take further necessary action as per above decision of NC.				

Case No.B-90	M/S DSM Infectives
Norms Committee Meeting No.8/10	F.No.01/82/050/00527/AM07
Meeting Date: 26.05.2009	RA F.No.22/24/040/00117/AM07
Adv.Lic.No.2210005749 dated 10.07.2006	

This case was listed for discussion in Norms Committee Meeting to be held on 26.5.2009 and firm was given an opportunity of personal hearing for explaining their case. Due to backlog, the agenda could not be taken up for discussion on due date. However, representatives of firm who had come for personal hearing were heard by the Committee.

S/Shri Ashok Dhingra, J. Sagar, Naresh Sharma and Ms Sonia Malik, on behalf of firm appeared before Committee and stated that they are leading manufacturer of Drugs and Drug Intermediates and 75% of their production is being exported. Shri Dhingra explained that the ad-hoc norms fixed by Committee in respect of export product 6-Amino Penicillanic Acid (6-APA) pertaining to subject advance licence are less than the actual requirement of the firm and they have furnished Production and Consumption data of the export product duly certified by the jurisdictional Excise Authorities for the last three years. Based on this data and comparative analysis of the norms asked for ad-hoc norms fixed in this case are less and as such they have requested for enhancement in the quantity of inputs. He further stated that they are manufacturing the export product through different route for which higher inputs are required. He further stated that they have already got enhanced quantity of inputs against various advance licences for this export product in the past. He was of the view that some inputs asked for by them are required for production of this export product but the same have not been allowed by the Committee.

Committee after detailed deliberations decided that there is no scope for enhancement in the quantity of inputs since the ad-hoc norms fixed in this case are based on comparison of data of various firms. Committee further decided that the representation, if any, of the firm for allowing inputs which have not been allowed by the Committee may be considered on merits.

Case No.B-91	M/S DSM Infectives
Norms Committee Meeting No.8/10	F.No.01/82/050/01422/AM06
Meeting Date: 26.05.2009	RA F.No.22/24/040/00060/AM06
Adv.Lic.No.2210005286 dated 28.02.2006	

This case was listed for discussion in Norms Committee Meeting to be held on 26.5.2009 and firm was given an opportunity of personal hearing for explaining their case. Due to backlog, the agenda could not be taken up for discussion on due date. However, representatives of firm who had come for personal hearing were heard by the Committee.

S/Shri Ashok Dhingra, J. Sagar, Naresh Sharma and Ms Sonia Malik, on behalf of firm appeared before Committee and stated that they are leading manufacturer of Drugs and Drug Intermediates and 75% of their production is being exported. Shri Dhingra explained that the ad-hoc norms fixed by Committee in respect of export product Amoxycillin

Trihydrate Enzymatic route pertaining to subject advance licence are less than the actual requirement of the firm and they have furnished Production and Consumption data of the export product duly certified by the jurisdictional Excise Authorities for the last three years. Based on this data and comparative analysis of the norms asked for ad-hoc norms fixed in this case are less and as such they have requested for enhancement in the quantity of inputs. He further stated that they are manufacturing the export product through different route for which higher inputs are required. He further stated that they have already got enhanced quantity of inputs against various advance licences for this export product in the past. He was of the view that some inputs asked for by them are required for production of this export product but the same have not been allowed by the Committee.

Committee after detailed deliberations decided that there is no scope for enhancement in the quantity of inputs since the ad-hoc norms fixed in this case are based on comparison of data of various firms. Committee further decided that the representation, if any, of the firm for allowing inputs which have not been allowed by the Committee may be considered on merits.

Case No.B-92	M/S DSM Infectives
Norms Committee Meeting No.8/10	F.No.01/82/050/00407/AM07
Meeting Date: 26.05.2009	RA F.No.22/24/040/00078/AM07
Adv.Lic.No.2210005658 dated 10.07.2006	

This case was listed for discussion in Norms Committee Meeting to be held on 26.5.2009 and firm was given an opportunity of personal hearing for explaining their case. Due to backlog, the agenda could not be taken up for discussion on due date. However, representatives of firm who had come for personal hearing were heard by the Committee.

S/Shri Ashok Dhingra, J. Sagar, Naresh Sharma and Ms Sonia Malik, on behalf of firm appeared before Committee and stated that they are leading manufacturer of Drugs and Drug Intermediates and 75% of their production is being exported. Shri Dhingra explained that the ad-hoc norms fixed by Committee in respect of export product Cloxacillin Sodium from Pen G route pertaining to this advance licence are less than the actual requirement of the firm and they have furnished Production and Consumption data of the export product duly certified by the jurisdictional Excise Authorities for the last three years. Based on this data and comparative analysis of the norms asked for ad-hoc norms fixed in this case are less and as such they have requested for enhancement in the quantity of inputs. He further stated that they are manufacturing the export product through different route for which higher inputs are required. He further stated that they have already got enhanced quantity of inputs against various advance licences for this export product in the past. He was of the view that some inputs asked for by them are required for production of this export product but the same have not been allowed by the Committee.

Committee after detailed deliberations decided that there is no scope for enhancement in the quantity of inputs since the ad-hoc norms fixed in this case are based on comparison of data of various firms. Committee further decided that the representation, if any, of the firm for allowing inputs which have not been allowed by the Committee may be considered on merits.
